A Mediterranean Diet in for Colon Cancer Prevention

描述（由申请人提供）：预防结肠癌的地中海饮食：流行病学和动物研究表明，传统克里特岛-地中海饮食的主要成分在预防结肠直肠癌的同时改善整体健康方面具有很大的前景。相对于美国饮食，地中海饮食中的n-6脂肪酸、多不饱和脂肪和红肉较低，而植物性食物和单不饱和脂肪的摄入量较高。这一建议背后的假设是，坚持地中海式饮食将导致人结肠粘膜中n-6脂肪酸减少，n-3和n-9脂肪酸增加。这与饮食的其他方面（例如水果和蔬菜中植物化学物质的摄入增加）一起，预期将正常结肠直肠粘膜中的类花生酸代谢调节至其抗癌状态，从而导致较低的结肠增殖。我们将招募120名结直肠癌风险增加的研究参与者。受试者将随机接受改良的地中海饮食或健康人群2010饮食，持续6个月。地中海饮食将旨在减少多不饱和脂肪的摄入量，增加单不饱和脂肪、水果和蔬菜的摄入量。预计这些饮食变化不仅会减少促炎介质和增加抗炎介质，而且还会改变由环氧合酶和脂氧合酶产生的类花生酸的类型。我们对这种新型交换列表饮食的初步测试表明，受试者可以进行非常大的饮食改变。将在干预前后分析饮食摄入数据、血液样本和来自软式乙状结肠镜检查的正常粘膜活检，并比较2个饮食组相对于基线的变化。具体终点是血液和粘膜中的脂肪酸和类胡萝卜素、粘膜中炎症介质的类型和水平以及粘膜中的增殖。我们预计，2010年健康人群饮食将导致相对于地中海饮食的最小变化。增加我们对饮食变化对人类粘膜影响的理解是评估饮食在预防结直肠癌中的潜力的基础。这些数据还将验证这些生物标志物作为筛选其他旨在减缓或逆转致癌作用的基于饮食和/或药物的干预措施的用途。如果结直肠癌风险的粘膜生物标志物（前列腺素E2，其他类花生酸，增殖）可以证明有益的影响，这些数据可以用来证明一个更大的，前瞻性的干预与疾病终点和更详细的饮食研究。

DESCRIPTION (provided by applicant): A Mediterranean Diet for Colon Cancer Prevention: Epidemiological and animal studies indicate that the major components of the traditional Cretan-Mediterranean diet have great promise for the prevention of colorectal cancer while improving overall health. Relative to the American diet, the Mediterranean diet is lower in n-6 fatty acids, polyunsaturated fats, and red meat while intakes of plant-based foods and monounsaturated fats are higher. The hypothesis behind this proposal is that adherence to a Mediterranean type of diet will result in a decrease in n-6 fatty acids and increased n-3 and n-9 fatty acids in human colonic mucosa. This, together with other aspects of the diet such as increased intakes of phytochemicals in fruits and vegetables, is expected to modulate eicosanoid metabolism in normal colorectal mucosa to its anticarcinogenic state resulting in lower colonic proliferation. We will recruit 120 study participants who are at increased risk of colorectal cancer. Subjects will be randomized to a modified Mediterranean diet or a Healthy People 2010 diet for 6 months. The Mediterranean diet will be designed to decrease polyunsaturated fat intake and to increase intakes of monounsaturated fats, fruits and vegetables. These dietary changes are expected to not only decrease pro-inflammatory mediators and increase anti-inflammatory mediators, but to also change the types of eicosanoids that are produced from cyclooxygenases and lipoxygenases. Our pilot testing of this novel exchange list diet indicates that subjects can make very large dietary changes. Dietary intake data, blood samples and biopsies of normal mucosa from flexible sigmoidoscopy will be analyzed before and after intervention, and changes from baseline will be compared in the 2 diet arms. The specific endpoints are fatty acids and carotenoids in blood and mucosa, the types and levels of inflammatory mediators in the mucosa, and proliferation in the mucosa. We expect that the Healthy People 2010 diet will result in minimal changes relative to the Mediterranean diet. Increasing our understanding of the effects of dietary changes on human mucosa is fundamental to evaluating the potential of diet in colorectal cancer prevention. Such data would also validate the use of these biomarkers as screen for other dietary and/or pharmaceutical-based interventions aimed at slowing or reversing carcinogenesis. If beneficial effects can be demonstrated in mucosal biomarkers of colorectal cancer risk (prostaglandin E2, other eicosanoids, proliferation), such data may be used to justify a larger, prospective intervention with disease endpoints and more detailed dietary studies.